External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home CTAD 2023
Roche and Genentech at

CTAD 2023

October 24 - October 27
Boston, USA
ctad-alzheimer.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
12:00 PM
Duration 96hrs Boston, USA
Alzheimer's disease linkage to evidence (AD-LINE) study: An analysis of concordance between clinical diagnosis and evidence of AD diagnosis in real-world US claims data
Desilu Glazebrook
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:00 PM
Duration 96hrs Boston, USA
RG6289, a new γ-secretase modulator for the treatment of Alzheimer’s disease: Dose selection for a phase II trial based on population PK/PD modeling
Agnes Portron
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 96hrs Boston, USA
Baseline risk factors for ARIA-E in the GRADUATE I and II studies of gantenerumab
Paul Delmar
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 96hrs Boston, USA
Assessing health system capacity for delivery of a disease-modifying therapy for Alzheimer’s disease: a multi-country analysis
Nathalie Budd
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:35 PM
Duration 10mins Boston, USA
THE ANTI-AMYLOID BETA “BRAIN SHUTTLE” ANTIBODY TRONTINEMAB RAPIDLY REDUCES AMYLOID PLAQUES IN PARTICIPANTS WITH ALZHEIMER’S DISEASE
Luka Kulic
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:00 PM
Duration 96hrs Boston, USA
Pharmacodynamic Effects of Semorinemab on Biomarkers of Tau, Synaptic Function, and Gliosis in a Phase 2 Trial of Mild-to-Moderate Alzheimer’s Disease
Stephen Schauer
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 96hrs Boston, USA
Measuring changes in longitudinal Tau-PET with [18F]MK-6240: group-level vs individualized ROIs definition
Nick Sidorenko
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 10mins Boston, USA
An exploration of amyloid removal measures in relation to clinical benefit: a review and meta-regression of anti-amyloid trials in AD.
Marzia A. Scelsi (lead author) / Paul Delmar (presenter)
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:00 PM
Duration 96hrs Boston, USA
Automated linguistic metrics from a novel, remote, smartphone-based self-assessment of cued narration and free recall correlate with brain atrophy in language and memory networks in early Alzheimer’s disease
Irma Kurniawan
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.